Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients

摘要: Background and objective Our was to investigate the efficacy safety of dexa methasone (DEX) implant for treatment pseudophakic cystoid macular edema (PCME) in diabetic patients. Study design This a prospective, non-randomized, interventional case series 43 participants. Eighteen patients were enrolled DEX group 25 an intravitreal triamcinolone acetonide (IVTA) group. Main outcome measures The primary measurement percentage who gained improvements more than ten letters best corrected visual acuity (BCVA) during 6 months follow-up. Other measurements included change BCVA, central thickness (CMT), number retreatments. evaluation with intraocular hypertension variation pressure (IOP) adverse events, such as conjunctival hemorrhage, eye pain, secondary infection, endophthalmitis, noninfectious inflammation, retinal detachment, migration, also recorded Results At month 1, we observed that gaining improvement similar both groups (P = 0.625). As IVTA retreated several times, this effect persisted throughout study 0.941 at 2, P 0.553 3, 0.856 6). Variations CMT noticed week 1 reached their maximum 1. No significant difference found between two 0.831 0.783 1). IOP its then decreased slightly. However, group, it increased continuously study. Conjunctival hemorrhage pain groups, but rated mild severity, no 0.184, 0.766, respectively). Conclusion Both implants could effectively restore function recover morphological PCME least months, repeated injection required is well tolerated. We suggest promising new therapeutic option PCME.